Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Consolidated Net Income (2023 - 2026)

ArriVent BioPharma has reported Consolidated Net Income over the past 4 years, most recently at -$43.3 million for Q1 2026.

  • Quarterly results put Consolidated Net Income at -$43.3 million for Q1 2026, up 32.72% from a year ago — trailing twelve months through Mar 2026 was -$145.2 million (down 13.95% YoY), and the annual figure for FY2025 was -$166.3 million, down 106.62%.
  • Consolidated Net Income reached -$43.3 million in Q1 2026 per AVBP's latest filing, down from -$35.5 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at -$12.2 million in Q1 2023 and bottomed at -$64.4 million in Q1 2025.
  • Median Consolidated Net Income over the past 4 years was -$21.6 million (2023), compared with a mean of -$27.6 million.
  • The largest annual shift saw Consolidated Net Income crashed 269.68% in 2025 before it soared 32.72% in 2026.
  • Over 4 years, Consolidated Net Income stood at -$21.2 million in 2023, then rose by 2.64% to -$20.6 million in 2024, then tumbled by 72.27% to -$35.5 million in 2025, then decreased by 21.88% to -$43.3 million in 2026.
  • Business Quant data shows Consolidated Net Income for AVBP at -$43.3 million in Q1 2026, -$35.5 million in Q4 2025, and -$35.0 million in Q3 2025.